An Open Trial to Asses the Tolerability of AVANZ Mite Mix Immunotherapy
Phase of Trial: Phase II/III
Latest Information Update: 08 Jan 2015
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors ALK-Abello
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Mar 2012 Additional lead trial investigator (Tabar AI) identified as reported by ClinicalTrials.gov.
- 30 Mar 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01568190).